PCSK9抑制剂的机制及其临床进展

陆言巧; 沈兰; 何奔

doi:10.13201/j.issn.1001-1439.2020.01.003

PCSK9抑制剂的机制及其临床进展

- 上海交通大学附属胸科医院心内科上海交通大学医学院临床研究中心(上海, 200030)
基金项目:
国家自然科学基金项目(No:81900308)

上海交通大学医学院临床研究项目(No:Dly201512)

详细信息

通讯作者: 何奔,E-mail:drheben@126.com

中图分类号: R541.7

收稿日期: 2019-07-17

Mechanism of PCSK9 inhibitor and its clinical progress

- Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Clinical Research Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200030, China

More Information

Corresponding author: HE Ben, E-mail: drheben@126.com

Received Date: 17 July 2019

摘要

摘要: 前蛋白转化酶枯草溶菌素9(PCSK9)是一类前蛋白转化酶家族蛋白酶K亚家族成员,与低密度脂蛋白(LDL)竞争性结合低密度脂蛋白受体(LDL-R),导致机体通过溶酶体降解LDL的水平降低,引起外周血LDL水平增高,从而引起血脂代谢异常、动脉粥样斑块等一系列病理生理过程,而PCSK9抑制剂可以有效地改善LDL降解减少的情况,降低机体LDL水平。本文系统性地回顾了PCSK9及其抑制剂的发现及其作用机制,并对近年来PCSK9抑制剂的研究进展及其在心血管系统方面临床应用作一综述。
- 前蛋白转化酶枯草溶菌素9抑制剂 /
- 低密度脂蛋白 /
- 动脉粥样硬化
Abstract: The proprotein convertase subtilisin 9(PCSK9) is a member of pro-protein convertase family.PCSK9 competes with low-density lipoprotein(LDL) for binding to low-density lipoprotein receptor(LDL-R).It reduces the degradation of LDL level through lysosomes and increases the concentration of LDL in peripheral blood.This process causes a series of pathophysiological processes such as abnormal lipid metabolism and atherosclerotic plaque.PCSK9 inhibitors can effectively improve the reduction of LDL degradation and reduce the level of LDL.This article systematically reviews the discovery and mechanism of PCSK9 inhibitors and summarizes the progress of PCSK9 inhibitors in recent years and its clinical application in cardiovascular system.
- PCSK9 inhibitor /
- low density lipoprotein /
- atherosclerosis

HTML全文

参考文献(45)

[1]	Seidah NG,Benjannet S,Wickham L,et al.The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):liver regeneration and neuronal differentiation[J].Proc Natl Acad Sci U S A,2003,100(3):928-933.
[2]	Tibolla G,Norata GD,Artali R,et al.Proprotein convertase subtilisin/kexin type 9 (PCSK9):from structure-function relation to therapeutic inhibition[J].Nutr Metab Cardiovasc Dis,2011,21(11):835-843.
[3]	Benjannet S,Rhainds D,Essalmani R,et al.NARC-1/PCSK9 and its natural mutants:zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol[J].J Biol Chem,2004,279(47):48865-48875.
[4]	Jeong HJ,Lee HS,Kim KS,et al.Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2[J].J Lipid Res,2008,49(2):399-409.
[5]	Hampton EN,Knuth MW,Li J,et al.The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain[J].Proc Natl Acad Sci U S A,2007,104(37):14604-14609.
[6]	Cunningham D,Danley DE,Geoghegan KF,et al.Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia[J].Nat Struct Mol Biol,2007,14(5):413-419.
[7]	Maxwell KN,Breslow JL.Adenoviral-mediated expression of PCSK9 in mice results in a low-density lipoprotein receptor knockout phenotype[J].Proc Natl Acad Sci U S A,2004,101(18):7100-7105.
[8]	Rashid S,Curtis DE,Garuti R,et al.Decreased plasma cholesterol and hypersensitivity to statins in mice lacking PCSK9[J].Proc Natl Acad Sci U S A,2005,102(15):5374-5379.
[9]	Kotowski IK,Pertsemlidis A,Luke A,et al.A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol[J].Am J Hum Genet,2006,78(3):410-422.
[10]	Clarke R,Emberson JR,Parish S,et al.Cholesterol fractions and apolipoproteins as risk factors for heart disease mortality in older men[J].Arch Intern Med,2007,167(13):1373-1378.
[11]	杨珍珍,赵存瑞,张锦,等.从血脂控制状况与支架内再狭窄的相关性看心脏康复管理的重要性[J].临床心血管病杂志,2017,33(7):650-652.
[12]	Cariou B,Le May C,Costet P.Clinical aspects of PCSK9[J].Atherosclerosis,2011,216(2):258-265.
[13]	Linton MF,Babaev VR,Gleaves LA,et al.A direct role for the macrophage low density lipoprotein receptor in atherosclerotic lesion formation[J].J Biol Chem,1999,274(27):19204-19210.
[14]	张辉,周文平,刘刚琼,等.前蛋白转化酶枯草杆菌蛋白酶9与稳定性冠心病患者冠状动脉病变严重程度的关系研究[J].临床心血管病杂志,2019,35(6):506-509.
[15]	Ricci C,Ruscica M,Camera M,et al.PCSK9 induces a pro-inflammatory response in macrophages[J].Sci Rep,2018,8(1):2267.
[16]	Tavori H,Giunzioni I,Predazzi IM,et al.Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE-and LDLR-mediated mechanisms[J].Cardiovasc Res,2016,110(2):268-278.
[17]	Zhu L,Giunzioni I,Tavori H,et al.Loss of macrophage low-density lipoprotein receptor-related protein 1 confers resistance to the antiatherogenic effects of tumor necrosis factor-alpha inhibition[J].Arterioscler Thromb Vasc Biol,2016,36(8):1483-1495.
[18]	Kang SW,Kim MS,Kim HS,et al.Celastrol attenuates adipokine resistin-associated matrix interaction and migration of vascular smooth muscle cells[J].J Cell Biochem,2013,114(2):398-408.
[19]	Tarkowski A,Bjersing J,Shestakov A,et al.Resistin competes with lipopolysaccharide for binding to toll-like receptor 4[J].J Cell Mol Med,2010,14(6b):1419-1431.
[20]	Tang ZH,Peng J,Ren Z,et al.New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-kappaB pathway[J].Atherosclerosis,2017,262:113-122.
[21]	Rosenson RS,Hegele RA,Fazio S,et al.The Evolving Future of PCSK9 Inhibitors[J].J Am Coll Cardiol,2018,72(3):314-329.
[22]	Bernelot Moens SJ,Neele AE,Kroon J,et al.PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia[J].Eur Heart J,2017,38(20):1584-1593.
[23]	Ikegami Y,Inoue I,Inoue K,et al.The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy[J].NPJ Aging Mech Dis,2018,4:7.
[24]	Rane PB,Patel J,Harrison DJ,et al.Patient characteristics and real-world treatment patterns among early users of PCSK9 inhibitors[J].Am J Cardiovasc Drugs,2018,18(2):103-108.
[25]	钟小燕,杨旭平,余彬,等.Evolocumab治疗血脂异常的疗效与安全性的系统评价[J].临床心血管病杂志,2016,32(1):19-24.
[26]	Blom DJ,Hala T,Bolognese M,et al.A 52-week placebo-controlled trial of evolocumab in hyperlipidemia[J].N Engl J Med,2014,370(19):1809-1819.
[27]	Raal FJ,Honarpour N,Blom DJ,et al.Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B):a randomised,double-blind,placebo-controlled trial[J].Lancet,2015,385(9965):341-350.
[28]	Raal FJ,Hovingh GK,Blom D,et al.Long-term treatment with evolocumab added to conventional drug therapy,with or without apheresis,in patients with homozygous familial hypercholesterolaemia:an interim subset analysis of the open-label TAUSSIG study[J].Lancet Diabetes Endocrinol,2017,5(4):280-290.
[29]	Cannon CP,Cariou B,Blom D,et al.Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins:the ODYSSEY COMBO II randomized controlled trial[J].Eur Heart J,2015,36(19):1186-1194.
[30]	Farnier M,Jones P,Severance R,et al.Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients:The ODYSSEY OPTIONS II randomized trial[J].Atherosclerosis,2016,244:138-146.
[31]	Kastelein JJ,Ginsberg HN,Langslet G,et al.ODYSSEY FH I and FH II:78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia[J].Eur Heart J,2015,36(43):2996-3003.
[32]	Kereiakes DJ,Robinson JG,Cannon CP,et al.Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy:The ODYSSEY COMBO I study[J].Am Heart J,2015,169(6):906-915.e913.
[33]	Roth EM,Taskinen MR,Ginsberg HN,et al.Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia:results of a 24 week,double-blind,randomized Phase 3 trial[J].Int J Cardiol,2014,176(1):55-61.
[34]	Hartgers ML,Defesche JC,Langslet G,et al.Alirocumab efficacy in patients with double heterozygous,compound heterozygous,or homozygous familial hypercholesterolemia[J].J Clin Lipidol,2018,12(2):390-396.e398.
[35]	Zhang Y,Ultsch M,Skelton NJ,et al.Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists[J].Nat Struct Mol Biol,2017,24(10):848-856.
[36]	Gustafsen C,Olsen D,Vilstrup J,et al.Heparan sulfate proteoglycans present PCSK9 to the LDL receptor[J].Nat Commun,2017,8(1):503.
[37]	Tajima T,Morita H,Ito K,et al.Blood lipid-related low-frequency variants in LDLR and PCSK9 are associated with onset age and risk of myocardial infarction in Japanese[J].Sci Rep,2018,8(1):8107.
[38]	Thakore PI,Kwon JB,Nelson CE,et al.RNA-guided transcriptional silencing in vivo with S.aureus CRISPR-Cas9 repressors[J].Nat Commun,2018,9(1):1674.
[39]	Rossidis AC,Stratigis JD,Chadwick AC,et al.In utero CRISPR-mediated therapeutic editing of metabolic genes[J].Nat Med,2018,24(10):1513-1518.
[40]	Jensen KK,Tadin-Strapps M,Wang SP,et al.Dose-dependent effects of siRNA-mediated inhibition of SCAP on PCSK9,LDLR,and plasma lipids in mouse and rhesus monkey[J].J Lipid Res,2016,57(12):2150-2162.
[41]	Fitzgerald K,White S,Borodovsky A,et al.A Highly Durable RNAi Therapeutic Inhibitor of PCSK9[J].N Engl J Med,2017,376(1):41-51.
[42]	Ray KK,Landmesser U,Leiter LA,et al.Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol[J].N Engl J Med,2017,376(15):1430-1440.
[43]	Lindholm MW,Elmen J,Fisker N,et al.PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates[J].Mol Ther,2012,20(2):376-381.
[44]	Pan Y,Zhou Y,Wu H,et al.A Therapeutic Peptide Vaccine Against PCSK9[J].Sci Rep,2017,7(1):12534.
[45]	Chen Z,Lichtor PA,Berliner AP,et al.Evolution of sequence-defined highly functionalized nucleic acid polymers[J].Nat Chem,2018,10(4):420-427.